Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity

Klaus Lehmann-Horn; Silke Kinzel; Linda Feldmann; Florentine Radelfahr; Bernhard Hemmer; Sarah Traffehn; Claude C.A. Bernard; Christine Stadelmann; Wolfgang Brück; Martin S. Weber

doi:10.1002/acn3.71

Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity

Klaus Lehmann-Horn, Silke Kinzel, Linda Feldmann, Florentine Radelfahr, Bernhard Hemmer, Sarah Traffehn, Claude C.A. Bernard, Christine Stadelmann, Wolfgang Brück, Martin S. Weber

Default

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Clinical trials revealed that systemic administration of B-cell-depleting anti-CD20 antibodies can hold lesion formation in the early relapsing-remitting phase of multiple sclerosis (MS). Throughout the secondary-progressive (SP) course of MS, pathogenic B cells may, however, progressively replicate within the central nervous system (CNS) itself, which is largely inaccessible to systemic anti-CD20 treatment. Utilizing the murine MS model of experimental autoimmune encephalomyelitis, we show that intrathecal (i.t.) administration of anti-CD20 alone very efficiently depletes meningeal B cells from established CNS lesions. In SP-MS patients, adding i.t. administration of anti-CD20 to its systemic use may be a valuable strategy to target pathogenic B-cell function.

Original language	English
Pages (from-to)	490-496
Number of pages	7
Journal	Annals of Clinical and Translational Neurology
Volume	1
Issue number	7
DOIs	https://doi.org/10.1002/acn3.71
State	Published - Jul 2014

Access to Document

10.1002/acn3.71

Cite this

@article{ba481ec7c9d549a5a6cd35fad0a33159,

title = "Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity",

abstract = "Clinical trials revealed that systemic administration of B-cell-depleting anti-CD20 antibodies can hold lesion formation in the early relapsing-remitting phase of multiple sclerosis (MS). Throughout the secondary-progressive (SP) course of MS, pathogenic B cells may, however, progressively replicate within the central nervous system (CNS) itself, which is largely inaccessible to systemic anti-CD20 treatment. Utilizing the murine MS model of experimental autoimmune encephalomyelitis, we show that intrathecal (i.t.) administration of anti-CD20 alone very efficiently depletes meningeal B cells from established CNS lesions. In SP-MS patients, adding i.t. administration of anti-CD20 to its systemic use may be a valuable strategy to target pathogenic B-cell function.",

author = "Klaus Lehmann-Horn and Silke Kinzel and Linda Feldmann and Florentine Radelfahr and Bernhard Hemmer and Sarah Traffehn and Bernard, {Claude C.A.} and Christine Stadelmann and Wolfgang Br{\"u}ck and Weber, {Martin S.}",

note = "Publisher Copyright: {\textcopyright} 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.",

year = "2014",

month = jul,

doi = "10.1002/acn3.71",

language = "English",

volume = "1",

pages = "490--496",

journal = "Annals of Clinical and Translational Neurology",

issn = "2328-9503",

publisher = "John Wiley & Sons Inc.",

number = "7",

}

TY - JOUR

T1 - Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity

AU - Lehmann-Horn, Klaus

AU - Kinzel, Silke

AU - Feldmann, Linda

AU - Radelfahr, Florentine

AU - Hemmer, Bernhard

AU - Traffehn, Sarah

AU - Bernard, Claude C.A.

AU - Stadelmann, Christine

AU - Brück, Wolfgang

AU - Weber, Martin S.

PY - 2014/7

Y1 - 2014/7

N2 - Clinical trials revealed that systemic administration of B-cell-depleting anti-CD20 antibodies can hold lesion formation in the early relapsing-remitting phase of multiple sclerosis (MS). Throughout the secondary-progressive (SP) course of MS, pathogenic B cells may, however, progressively replicate within the central nervous system (CNS) itself, which is largely inaccessible to systemic anti-CD20 treatment. Utilizing the murine MS model of experimental autoimmune encephalomyelitis, we show that intrathecal (i.t.) administration of anti-CD20 alone very efficiently depletes meningeal B cells from established CNS lesions. In SP-MS patients, adding i.t. administration of anti-CD20 to its systemic use may be a valuable strategy to target pathogenic B-cell function.

AB - Clinical trials revealed that systemic administration of B-cell-depleting anti-CD20 antibodies can hold lesion formation in the early relapsing-remitting phase of multiple sclerosis (MS). Throughout the secondary-progressive (SP) course of MS, pathogenic B cells may, however, progressively replicate within the central nervous system (CNS) itself, which is largely inaccessible to systemic anti-CD20 treatment. Utilizing the murine MS model of experimental autoimmune encephalomyelitis, we show that intrathecal (i.t.) administration of anti-CD20 alone very efficiently depletes meningeal B cells from established CNS lesions. In SP-MS patients, adding i.t. administration of anti-CD20 to its systemic use may be a valuable strategy to target pathogenic B-cell function.

UR - http://www.scopus.com/inward/record.url?scp=84950279079&partnerID=8YFLogxK

U2 - 10.1002/acn3.71

DO - 10.1002/acn3.71

M3 - Article

AN - SCOPUS:84950279079

SN - 2328-9503

VL - 1

SP - 490

EP - 496

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

IS - 7

ER -

Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity

Abstract

Access to Document

Other files and links

Fingerprint

Cite this